286 related articles for article (PubMed ID: 27783278)
21. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
22. Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.
Park SS; Uzelac A; Kotsopoulos J
Hered Cancer Clin Pract; 2022 Apr; 20(1):14. PubMed ID: 35418083
[TBL] [Abstract][Full Text] [Related]
23. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
24. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
25. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
26. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
27. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
28. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
29. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
[TBL] [Abstract][Full Text] [Related]
30. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
31. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
Sänger N; Ruckhäberle E; Bianchini G; Heinrich T; Milde-Langosch K; Müller V; Rody A; Solomayer EF; Fehm T; Holtrich U; Becker S; Karn T
Mol Oncol; 2014 Oct; 8(7):1196-207. PubMed ID: 24785095
[TBL] [Abstract][Full Text] [Related]
32. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
33. Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.
Warren JT; Zou W; Decker CE; Rohatgi N; Nelson CA; Fremont DH; Teitelbaum SL
J Cell Biochem; 2015 Nov; 116(11):2476-83. PubMed ID: 25864714
[TBL] [Abstract][Full Text] [Related]
34. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.
Schieferdecker A; Voigt M; Riecken K; Braig F; Schinke T; Loges S; Bokemeyer C; Fehse B; Binder M
Oncotarget; 2014 Aug; 5(16):6647-53. PubMed ID: 25138051
[TBL] [Abstract][Full Text] [Related]
35. Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
Neirich L; Yahiaoui-Doktor M; Lammert J; Basrai M; Seethaler B; Berling-Ernst A; Ramser J; Quante AS; Schmidt T; Niederberger U; Rhiem K; Schmutzler R; Engel C; Bischoff SC; Halle M; Kiechle M; Grill S
Breast Cancer Res Treat; 2021 Dec; 190(3):463-475. PubMed ID: 34570303
[TBL] [Abstract][Full Text] [Related]
36. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
37. RANKL/RANK - from bone physiology to breast cancer.
Sigl V; Penninger JM
Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
[TBL] [Abstract][Full Text] [Related]
38. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
39. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
[TBL] [Abstract][Full Text] [Related]
40. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
